Full Press Release Details
Medical Granted Registered Trademark from The U.S. Patent and Trademark Office
Mass., November 8, 2023 - Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY Robotic
Surgical System, the first single-use endovascular robotic system, today announced it had been granted a registered trademark from the
US Patent and Trademark Office. The trademark "One & Done " was given to the feature of the LIBERTY Robotic
Surgical System which is being developed to integrate guidewires, microcatheters and other instruments required for complete endovascular
procedures using the device.
this trademark, the Company continues to expand its proprietary assets, including numerous approved and pending patents all over the
world, and differentiate its product's capabilities.
Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies,
with the goals of improving clinical outcomes for patients and increasing accessibility through the natural and artificial lumens within
LIBERTY Robotic Surgical System aims to improve the way surgical robotics are being used in endovascular procedures today, by eliminating
the need for large, cumbersome, and expensive capital equipment, while reducing radiation exposure and physician strain. The Company
believes the LIBERTY Robotic Surgical System's remote operation has the potential to be the first system to democratize endovascular
interventional procedures.
information about Microbot Medical is available at http://www.microbotmedical.com.
to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities
for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or
prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform
Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that
contain words such as "will," "believes," "plans," "anticipates," "expects"
and "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, market conditions, risks inherent in the development and/or commercialization of LIBERTY,
the outcome of its studies to evaluate LIBERTY, whether the Company's core business focus program and cost reduction plan are sufficient
to enable the Company to continue to focus on its LIBERTY technology while it stabilizes its financial condition and seeks additional
working capital, any failure or inability to recruit physicians and clinicians to serve as primary investigators to conduct regulatory
studies which could adversely affect or delay such studies, uncertainty in the results of pre-clinical and clinical trials or regulatory
pathways and regulatory approvals, disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, such as
employees of Microbot and its vendors and business partners being called to active military duty, any lingering uncertainty resulting
from the COVID-19 pandemic, need and ability to obtain future capital, and maintenance of intellectual property rights. Additional information
on risks facing Microbot Medical can be found under the heading "Risk Factors" in Microbot Medical's periodic reports
filed with the Securities and Exchange Commission (SEC), which are available on the SEC's web site at www.sec.gov. Microbot Medical
disclaims any intent or obligation to update these forward-looking statements, except as required by law.